Abstract:Abstract Abstract 5105 Objective: To improve the understanding of natural killer (NK)/T cell lymphoma (NK/TCL) with poor prognosis and provide experiential references via a restrospective analysis of the clinical and pathological features. Methods: 117 NK/TCL cases in single center of Northwestern China from April 2009 to April 2012 were retrospectively analyzed on their pathologic diagnosis and clinical manifestations, especially primary sites. Pathologic examinations mainly depended on morphology, immunohistochemisty, In situ hybridizationc and polymerase chain reaction (PCR). Immunohistochemical staining for immunophenotype (LCA, CD3, CD20, CD29a, CD45RO, CD56, TIA-1 and Granzyme B), In situ hybridization for Epstein - Barr virus (EBV) small encoded RNA(EBER) and PCR for the amount of EBV DNA in whole-blood and T-cell receptor (TCR) gene rearrangement were performed respectively. For nasal NK/TCL, combined chemotherapy and radiotherapy were indicated for stage I/II disease. Chemotherapy was the main treatment for stage III/IV NK/TCL. Regimens contained drugs not affected by P-glycoprotein, particularly in combination with L-asparaginase, or pegaspargase. Overall survival (OS) according to clinical characteristics was analyzed. Results: NK/TCL could be diagnosed via its typical clinical symptom, pathological morphology, phenotype and EBER. 117 cases were nasal or extranodal NK/TCL. The median age was 39 years old. The median survival was 11 months. The primary nasal NK/TCL was 95, accounting for 81. 2% (95/117) and their average Ki67 was 78. 34%+21. 6%. Other primary extranodal NK/TCL was 22, accunting for 18. 8%(22/117), as follows: 4 primary posterior pharyngeal wall cases with average Ki67 60%+11. 3%, 4 primary lymph nodes cases with average Ki67 50%+10. 6%, 4 primary skin cases with average Ki67 45%+8. 6%, 3 primary tonsil cases with average Ki67 67. 3%+2. 8%, 1 primary laryngeal case with Ki67 80%, 1 primary liver case with Ki67 was 90%, 1 primary intestinal case with Ki67 80%, 1 primary tongue case with Ki67 66%, 2 primary central nervous system cases with average Ki67 less than 30%, 1 primary testis case with Ki67 56%. It was found that 31 patients with primary liver and intestinal or Ki67 greater than 80% were dead in first year. Patients with primary liver and intestinal had higher Ki67 than patients with primary nasal (P <0. 01). Rate of 2 year(2y) OS of 45 patients with Ki67 from 60% to 80% was 60% as compared to 86. 3% of rate of OS of 33 patients with Ki67 from 30% to 50% (P <0. 05)and 100% of rate of OS of patients with Ki67 less than 30%(P <0. 01). Rate of 2y OS of 8 CD56− patients whose TCR was positive and primary sites were nasal was 100% higher than 67% of 109 CD56+ patients(P <0. 01). It was implied that nasal NK/TCL was of T-cell origin. Rate of 2y OS of 7 EBER− patients was 100% higher than 58% of 110 EBER+ patients(P <0. 01). The EBV–DNA was detected in 42 samples with less than 104 copies/ml in whole blood and rate of 2y OS of these patients was 55%+16%. There were 4 samples with more than 105 copie/ml EBV–DNA in whole blood and CD56+. The rate of 2y OS of these patients was 22%+9%. Conclusion: It was implied that Ki67, CD56, EBER, EBV-DNA and primary site was related with the prognosis of NK/TCL. It was also showed that NK/TCL of T-cell origin had a trend for better survival. However, it needs further and more clinical observation and verification to judge if they could be additional markers for prognostication and clinical stratification to be incorporated in clinical individual management algorithms. Disclosures: No relevant conflicts of interest to declare.

Immunophenotypic Characteristics and Clinical Relevance of CD56+ and CD56− Extranodal Nasal-Type Natural Killer/t-Cell Lymphoma

Identification of Immunophenotypic Subtypes with Different Prognoses in Extranodal Natural Killer/t-Cell Lymphoma, Nasal Type

Immunophenotypic and Clinical Differences Between the Nasal and Extranasal Subtypes of Upper Aerodigestive Tract Natural Killer/T-Cell Lymphoma

CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis

Clinicolpathological Characteristics of 117 Cases of Extranodal NK/T Cell Lymphoma, Nasal Type

Analysis Of Clinical And Pathological Features Of 117 Chinese Cases Of Natural Killer/T Cell Lymphoma

Expression of CD117 and PDGFRa in Extranodular NK/T Cell Lymphoma (Nasal Type)

Clinicopathologic and Immunophenotypic Features of Primary Intestinal Extranodal NK/T-Cell Lymphoma, Nasal Type

Clinicopathology, Immunophenotype, T Cell Receptor Gene Rearrangement, Epstein-Barr Virus Status and P53 Gene Mutation of Cutaneous Extranodal NK/T-cell Lymphoma, Nasal-Type.

The clinical study of extranodal natural killer cell lymphoma, nasal type

Immunohistochemical and genetic analysis of Chinese nasal natural killer/T-cell lymphomas.

Clinical Analysis Of 120 Cases Of Natural Killer/T Cell Lymphoma, Nasal Type By Single Hospital In The North-Western China

CD56-Negative Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Study in 443 Patients Treated by Chemotherapy With or Without Asparaginase

Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma.

Genomic Profiling Identifies Distinct Genetic Subtypes in Extra-Nodal Natural Killer/t-Cell Lymphoma.

Characteristics and Clinical Implications of the Nasal Microbiota in Extranodal NK/T-Cell Lymphoma, Nasal Type

Two Distinct Subtypes of Nasal-type NK/T Cell Lymphoma: Clinical Features and Treatment Outcome According to Primary Site of the Nasal Cavity or Waldeyer's Ring

Comparison of Diagnostic Cytomorphology of Natural Killer/T-Cell Lymphoma (Nasal Type) in Conventional Smears, Liquid-Based Preparations, and Histopathology

The extent of cutaneous lesions predicts outcome in extranodal nasal-type natural killer/T-cell lymphoma of the upper aerodigestive tract with secondary cutaneous involvement.

Immunophenotype and Expression of Cytotoxic Granule Proteins of Nasal NK/T Cell Lymphoma and Its Significance

Variable Clinical Presentations of Nasal and Waldeyer Ring Natural Killer/T-Cell Lymphoma